The role of B cells in regulating the magnitude of immune response

Microbiology and Immunology

Volumn 54, Issue 8, 2010, Pages 487-490

  Nagafuchi, Seiho ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Autoimmune disease; B cell; Immunoregulation; Rituximab

Indexed keywords

AUTOANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; LYMPHOCYTE MEMBRANE IMMUNOGLOBULIN; RITUXIMAB;

ANTIGEN DETECTION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION; INFECTION CONTROL; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; REVIEW; SPLEEN; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; IMMUNOLOGY;

ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS; INFECTION;

EID: 77955001099     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2010.00235.x     Document Type: Review

References (20)

1. Dörner T., Radbruch A., Burmester G.R. (2009) B-cell-directed therapies for autoimmune disease. Nat Rev Rehumatol 5: 433-441.
2. Levesque M.C. (2009) Translational mini-review series on B cell-directed therapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol 157: 198-208.
3. Mease P.J. (2008) B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. JRheumatol 35: 1245-1255.
4. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., et al. (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. NEnglJMed 361: 2143-2152.
5. Suarez-Pinzon W.L., Rabinovitch A. (2001) Approaches to type 1 diabetes prevention by intervention on cytokine immunoregulatory circuits. Int J Exp Diab Res 2: 3-17.
6. Silverman G.J., Boyle D.L. (2008) Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol Rev 223: 175-185.
7. Sanz I. (2009) The conundrum of B cell depletion in SLE. Nat Rev Rheumatol 5: 304-5.
8. Schlomchik M.J. (2009) Activating systemic autoimmunity: B's, T's, and tolls. Curr Opin Immunol 21: 626-633.
9. Lund F.E. (2008) Cytokine-producing B-lymphocytes-key regulators of immunity. Curr Opin Immunol 20: 332-338.
10. Armed R., Carvone F., Ley T., O'Garra A., Reiner S., Schreiber R., et al. (2008) Dendritic cells process antigen from a wide array of pathogens. In:Murphy K., Traversm P., Walport M., eds. Janeway s Immunobiology, 7th edn. New York and London: Garland Science, pp. 334-336.
11. Jaiswal A.I., Croft M. (1997) CD40 ligand induction of T cell subsets by peptide-presenting B cells. J Immunol 159: 2282-2291.
12. Nagafuchi S., Katsuta H., Anzai K. (2010) Rituximab, B-lymphocyte depletion, and beta-cell function. N Engl J Med 362: 761.
13. Kondo S., Iwata I, Anzai K., Akashi T., Wakana S., Ohkubo K., et al. (2000) Suppression of insulitis and diabetes in B cell-deficient mice treated with streptozocin: B cells are essential for T cell receptor clonotype spreading in islet-infiltrating T cells. Int Immunol 12: 1075-1083.
14. Akashi T., Nagafuchi S., Kitamura D., Anzai K., Wang J., Taniuchi I., et al. (1977) Direct evidence for the contribution of B cells to the progression ofinsulitis and the development ofdiabetes in non-obese diabetic mice. Int Immunol 9: 1159-1164.
15. Hu Cy., Rodriguez-Pinto D., Du W., Ahuja A., Henegarju O., Wong F.S., et al. (2007) Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 117: 3857-3867.
16. Xiu Y., Wong C.P., Bounaziz J.D., Hamaguchi Y., Wang Y., Pop S.M., et al. (2008) B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in non-obese diabetic mice despite isotype-specific differences in FcgR effector functions. J Immunol 180: 2863-2875.
17. Barnadas M.A., Roe E., Brunet S., Garcia P., Bergua P., Pimentel L., et al. (2006) Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature. J EADV 20: 69-74.
18. Lutt J.R., Pisculli M.L., Weinblatt M.E., Deodhar A., Winthrop K.L. (2008) Severe nontuberculous mycobacterial infection in 2 patients receiving Rituximab for refractory myositis. J Rheumatol 35: 1683-1686.
19. Laubach J., Bawn S.D., Gordon L.I., Winter J.N., Furman R.R., Vose J.M., et al. (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113: 4834-4840.
20. Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., Kaveri S.V. (2004) Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?. Trends Pharmacol Sci 25: 305-310.